SOURCE: Quture International, Inc.

Quture International, Inc.

April 16, 2013 08:00 ET

Quture (QUTR) and New Health Analytics Jointly Announce Joint Marketing & Sales Agreement

Companies Announce Their Intention to Achieve Revenue With Joint Marketing and Sales of Licenses to Their Products to Leverage QualOptima Now Proven in Clinical Trials

DAYTONA BEACH, FL and RICHMOND, VA--(Marketwired - Apr 16, 2013) - Quture International, Inc. (OTCQB: QUTR) and SMA Informatics Partners LLC, doing business as New Health Analytics, an LLC organized under the laws of Virginia (NHA) ( today jointly announce successful completion of their Joint Marketing & Sales Agreement. The Parties intend to immediately pursue joint sale and installation of their integrated products for performance and outcomes analytics in three (3) customer sites to demonstrate the value proposition of their products individually and enhanced operating in tandem. Joint sales will be to existing and prospective customers of the Parties through joint licensing and end-user agreements. Terms of the joint sale of licensing were not disclosed but are substantial for the financial integrity and prospectively for both Quture and NHA.

"Collaboration with Quture advances our product offerings and sales opportunities," said Louis F. Rossiter, PhD, Co-Founder and Chief of Scientific Methods for NHA. "We believe the clinical performance and outcomes methods, technology, and metrics of Quture integrated with NHA methods and technology provides exponentially advanced product offerings to our customers. The commitment of NHA to its health care analytics, ongoing professional practice evaluation (OPPE), and surgical outcomes (SOIX) provide dramatic opportunities for our companies to hospitals, surgery centers, physicians and payers."

Quture recently announced completion of data collection and is now preparing to announce ROI advantages to hospitals, physicians, payers, regulators, suppliers and consumers of health care from the Clinical Trial at the University of Miami, Miller School of Medicine and Jackson Memorial Hospital with Keith A. Candiotti, MD, and InterSystems Corporation, Cambridge, MA ( The Company is rapidly transitioning to revenue and fundamentals from such sales and marketing agreements. Improving clinical outcomes and addressing the inherent financial business intelligence analytics opportunities to customers is the strength of both Quture and NHA.

"We anticipate a series of announcements of sales of the QualOptima product and its Applications in the immediate future," said Landon Feazell, Chairman & CEO of Quture. "NHA is a remarkable opportunity to collaborate with extraordinary experts such as Dr. Rossiter and Warren Brennan with SMA Informatics. Our performance and analytics products do not compete but mutually strengthen each other's technology offerings and services. NHA's focus is traditionally in analytics and technology for claims and administrative data, which is an important adjunct to real-time clinical analytics of Quture. Their customer base combined with prospective customers of Quture and jointly put both companies on the fast track to extraordinary revenue."

"NHA and SMA Informatics are excited about joint sales and marketing of NHA's Readmissions Evaluator Medicare Assessment and Payment Impact Analysis (which converts ICD-9 codes to ICD-10 codes) with Quture's QualOptima Performance and Peer Review Application," said Warren Brennan, MBA. "We are mutually exploring licensing other technologies and collaborating in other existing technologies and the development of joint technologies, especially with surgical outcomes as an existing NHA product. I have worked with Landon Feazell and his companies previously, and we are enthusiastic about our opportunities to jointly market and sell our products and services again, not to mention new technology jointly."

Dr. Rossiter is joining the faculty of the National Healthcare Performance and Outcomes Summit in Washington, D.C., September 16-18, 2013 ( Feazell is also the Co-Chairman of the Summit, and Quture is a founding sponsor.

Quture International, Inc. (QUTR) is the proven and experienced clinical performance and outcomes analytics company in the United States. The vision of Quture is to connect all constituents in the global health and health care community to clinically and financially focused and sound data transformed through analytics to knowledge that empowers data-driven decisions for results-driven success. As a "Breakthrough" Application Partner of InterSystems Corporation, Quture's technology for capturing, integrating and aggregating data on the InterSystems Enterprise platform is unequalled. The Company's unique product QualOptima develops a second generation CLINICAL database implementing Quture's core competence of clinical content with evidence-based metrics developed for more than 35 years. QualOptima empowers clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned to become the leading clinical knowledge company in the world. Quture International is a Nevada corporation trading under the symbol QUTR.

Based in Richmond, VA, New Health Analytics offers hospitals, ambulatory surgery centers, integrated delivery systems, health plans and physician organizations a complete health information system for clinical integration. We help you with your day-to-day needs for data analysis to succeed with managed care companies, accountable care organizations and pay-for-performance systems. We do this by enabling the way you share of clinical information; coordinate treatment between primary care physicians and specialists; apply medical treatment guidelines; and monitor the adherence of practitioners compared to others. With our expertise in analytics and economics, we offer a new healthcare information system that combines a data warehouse with an analytical workstation that can be implemented in weeks, not months. NHA currently offers three (3) basic product solutions. The first solution, known as CiManager®, helps hospitals and hospital networks, assess, identify and demonstrate improved quality and outcomes, monitor measures of performance and patient safety and uncover key areas for financial and operational efficiencies. The second, known as PCA Plus™, provides hospitals and hospital networks with healthcare planning, strategic management, and market research for benchmarking current operations, forecasting and improving productivity and profitability by detailed service lines. Over the years, we have augmented the internal capacity of hospitals, physician organizations, health plans, life science organization, medical device companies, associations and foundations with the analytic power available from the huge statewide patient-level databases we routinely maintain. The third, known as SOIX® is for ambulatory surgery centers to benchmark, procedure by procedure, their clinical outcomes and patient satisfaction for accreditation, risk management and improved patient outcomes.

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.

Contact Information

  • Contact:
    Mele Telitz
    Director of Communications
    855.740.QUTR (7878)

    Warren Brennan, MBA
    Co-Founder & COO

    Constellation Asset Advisors, Inc.
    Jens Dalsgaard
    +1 (415) 524-8500

    Infinity Advisors
    Mark Kroeger
    (239) 495-6125